



RECEIVED

DEC 03 2001

TECH CENTER 1600,2900

CERTIFICATE OF MAILING  
UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington DC 20231 on

26 NOVEMBER 2001 COM  
HUESCHEN AND SAGE

G. PATRICK SAGE  
Dated: 26 NOVEMBER 2001

PF82PCTSEQ

\* \* \* \* \*

Applicant : Christine ANDREONI, et al.

Serial No. : 09/647,309

Filed : January 3, 2001

Title : USE OF ACTIVE P40 CONJUGATES FOR NASAL DELIVERY

Art Unit : 1645

Examiner : Ilesha P. FIELDS, Esq.

BEST AVAILABLE COPY

\* \* \* \* \*

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RESPONSE AND ELECTION UNDER 37 CFR §§ 1.111 AND 1.115

Sir:

Responsive to the Office Action, a Restriction Requirement, dated October 26, 2001, the applicants elect, with traverse, to prosecute the invention of Group "a", and more specifically an antigen. The applicants note, as well, that certain claims require amendment based on the Sequence Listing.

IN THE CLAIMS:

Claim 25: Kindly amend as follows, a marked-up copy is attached hereto:

- 25 - (amended)

B<sup>1</sup> Use of Claim 22 wherein at least one fragment has the sequence SEQ ID No 2.